US20030003171A1 - Biologically active chloroform fraction of an extract obtained from a mangroone plant Salvadora persica L - Google Patents
Biologically active chloroform fraction of an extract obtained from a mangroone plant Salvadora persica L Download PDFInfo
- Publication number
- US20030003171A1 US20030003171A1 US09/818,691 US81869101A US2003003171A1 US 20030003171 A1 US20030003171 A1 US 20030003171A1 US 81869101 A US81869101 A US 81869101A US 2003003171 A1 US2003003171 A1 US 2003003171A1
- Authority
- US
- United States
- Prior art keywords
- extract
- plant
- salvadora persica
- subject
- crude extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000002036 chloroform fraction Substances 0.000 title claims abstract description 30
- 239000000284 extract Substances 0.000 title claims description 65
- 240000007542 Salvadora persica Species 0.000 title claims description 47
- 238000000034 method Methods 0.000 claims abstract description 55
- 150000001875 compounds Chemical class 0.000 claims abstract description 45
- 239000000287 crude extract Substances 0.000 claims abstract description 35
- 230000008569 process Effects 0.000 claims abstract description 22
- 230000003288 anthiarrhythmic effect Effects 0.000 claims abstract description 10
- 230000002921 anti-spasmodic effect Effects 0.000 claims abstract description 10
- 239000000812 cholinergic antagonist Substances 0.000 claims abstract description 9
- 235000006580 Salvadora persica Nutrition 0.000 claims description 23
- 239000000203 mixture Substances 0.000 claims description 23
- FLIACVVOZYBSBS-UHFFFAOYSA-N Methyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC FLIACVVOZYBSBS-UHFFFAOYSA-N 0.000 claims description 22
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 18
- 241000196324 Embryophyta Species 0.000 claims description 16
- JYDNKGUBLIKNAM-UHFFFAOYSA-N Oxyallobutulin Natural products C1CC(=O)C(C)(C)C2CCC3(C)C4(C)CCC5(CO)CCC(C(=C)C)C5C4CCC3C21C JYDNKGUBLIKNAM-UHFFFAOYSA-N 0.000 claims description 14
- FVWJYYTZTCVBKE-ROUWMTJPSA-N betulin Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(CO)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C FVWJYYTZTCVBKE-ROUWMTJPSA-N 0.000 claims description 14
- MVIRREHRVZLANQ-UHFFFAOYSA-N betulin Natural products CC(=O)OC1CCC2(C)C(CCC3(C)C2CC=C4C5C(CCC5(CO)CCC34C)C(=C)C)C1(C)C MVIRREHRVZLANQ-UHFFFAOYSA-N 0.000 claims description 14
- 239000000654 additive Substances 0.000 claims description 13
- 230000001078 anti-cholinergic effect Effects 0.000 claims description 13
- 238000004809 thin layer chromatography Methods 0.000 claims description 13
- 230000008018 melting Effects 0.000 claims description 12
- 238000002844 melting Methods 0.000 claims description 12
- MQYXUWHLBZFQQO-QGTGJCAVSA-N lupeol Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C MQYXUWHLBZFQQO-QGTGJCAVSA-N 0.000 claims description 11
- PKGKOZOYXQMJNG-UHFFFAOYSA-N lupeol Natural products CC(=C)C1CC2C(C)(CCC3C4(C)CCC5C(C)(C)C(O)CCC5(C)C4CCC23C)C1 PKGKOZOYXQMJNG-UHFFFAOYSA-N 0.000 claims description 11
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 claims description 10
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 10
- JFSHUTJDVKUMTJ-QHPUVITPSA-N beta-amyrin Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C JFSHUTJDVKUMTJ-QHPUVITPSA-N 0.000 claims description 10
- 150000003648 triterpenes Chemical class 0.000 claims description 10
- 229940096998 ursolic acid Drugs 0.000 claims description 10
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 claims description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 9
- 239000003208 petroleum Substances 0.000 claims description 9
- 238000012360 testing method Methods 0.000 claims description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 8
- FSLPMRQHCOLESF-UHFFFAOYSA-N alpha-amyrenol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C)C(C)C5C4=CCC3C21C FSLPMRQHCOLESF-UHFFFAOYSA-N 0.000 claims description 8
- QQFMRPIKDLHLKB-UHFFFAOYSA-N beta-amyrin Natural products CC1C2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C)CCC1(C)C QQFMRPIKDLHLKB-UHFFFAOYSA-N 0.000 claims description 8
- PDNLMONKODEGSE-UHFFFAOYSA-N beta-amyrin acetate Natural products CC(=O)OC1CCC2(C)C(CCC3(C)C4(C)CCC5(C)CCC(C)(C)CC5C4=CCC23C)C1(C)C PDNLMONKODEGSE-UHFFFAOYSA-N 0.000 claims description 8
- 239000000741 silica gel Substances 0.000 claims description 8
- 229910002027 silica gel Inorganic materials 0.000 claims description 8
- 230000006793 arrhythmia Effects 0.000 claims description 6
- 206010003119 arrhythmia Diseases 0.000 claims description 6
- 238000000605 extraction Methods 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 238000000746 purification Methods 0.000 claims description 6
- -1 Aliphatic Ester Chemical class 0.000 claims description 5
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 5
- 239000012223 aqueous fraction Substances 0.000 claims description 5
- 208000006673 asthma Diseases 0.000 claims description 5
- 238000012545 processing Methods 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- 241001465754 Metazoa Species 0.000 claims description 4
- 239000002034 butanolic fraction Substances 0.000 claims description 4
- 238000004440 column chromatography Methods 0.000 claims description 4
- 208000030603 inherited susceptibility to asthma Diseases 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 230000001747 exhibiting effect Effects 0.000 claims description 3
- 239000000401 methanolic extract Substances 0.000 claims description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 2
- 208000005392 Spasm Diseases 0.000 claims description 2
- 229910052740 iodine Inorganic materials 0.000 claims description 2
- 239000011630 iodine Substances 0.000 claims description 2
- 238000004611 spectroscopical analysis Methods 0.000 claims description 2
- 238000005507 spraying Methods 0.000 claims description 2
- 239000001117 sulphuric acid Substances 0.000 claims description 2
- 235000011149 sulphuric acid Nutrition 0.000 claims description 2
- VLRYIIPJIVGFIV-QQSFYHFXSA-N maniladiol Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)C[C@H](O)[C@@]5(C)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C VLRYIIPJIVGFIV-QQSFYHFXSA-N 0.000 claims 2
- 238000007605 air drying Methods 0.000 claims 1
- HYGYSIDIKIGPJA-UHFFFAOYSA-N chloroform;ethyl acetate;methanol Chemical compound OC.ClC(Cl)Cl.CCOC(C)=O HYGYSIDIKIGPJA-UHFFFAOYSA-N 0.000 claims 1
- 230000001713 cholinergic effect Effects 0.000 claims 1
- 238000007796 conventional method Methods 0.000 claims 1
- 238000001704 evaporation Methods 0.000 claims 1
- 238000001914 filtration Methods 0.000 claims 1
- 240000002044 Rhizophora apiculata Species 0.000 abstract description 15
- 230000000144 pharmacologic effect Effects 0.000 abstract description 12
- 238000012216 screening Methods 0.000 abstract description 6
- 239000003416 antiarrhythmic agent Substances 0.000 abstract description 3
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 abstract description 2
- 230000000975 bioactive effect Effects 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 21
- 241000700199 Cavia porcellus Species 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 239000003814 drug Substances 0.000 description 12
- QGJZLNKBHJESQX-FZFNOLFKSA-N betulinic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C QGJZLNKBHJESQX-FZFNOLFKSA-N 0.000 description 11
- 210000003405 ileum Anatomy 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- QGJZLNKBHJESQX-UHFFFAOYSA-N 3-Epi-Betulin-Saeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(=C)C)C5C4CCC3C21C QGJZLNKBHJESQX-UHFFFAOYSA-N 0.000 description 10
- CLOUCVRNYSHRCF-UHFFFAOYSA-N 3beta-Hydroxy-20(29)-Lupen-3,27-oic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C(O)=O)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C CLOUCVRNYSHRCF-UHFFFAOYSA-N 0.000 description 10
- DIZWSDNSTNAYHK-XGWVBXMLSA-N Betulinic acid Natural products CC(=C)[C@@H]1C[C@H]([C@H]2CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(=O)O DIZWSDNSTNAYHK-XGWVBXMLSA-N 0.000 description 10
- PZXJOHSZQAEJFE-UHFFFAOYSA-N dihydrobetulinic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(C)C)C5C4CCC3C21C PZXJOHSZQAEJFE-UHFFFAOYSA-N 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- MQYXUWHLBZFQQO-UHFFFAOYSA-N nepehinol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C MQYXUWHLBZFQQO-UHFFFAOYSA-N 0.000 description 10
- 210000002837 heart atrium Anatomy 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 230000008602 contraction Effects 0.000 description 8
- 238000005194 fractionation Methods 0.000 description 7
- 238000002955 isolation Methods 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 6
- 230000003595 spectral effect Effects 0.000 description 6
- 239000000470 constituent Substances 0.000 description 5
- 239000003480 eluent Substances 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 244000025254 Cannabis sativa Species 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 4
- 229960004373 acetylcholine Drugs 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000002451 electron ionisation mass spectrometry Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- IECQULMJVNSKDB-RCWTXCDDSA-N 3-[(2s)-1-methylpyrrolidin-2-yl]pyridine;sulfuric acid Chemical compound OS(O)(=O)=O.CN1CCC[C@H]1C1=CC=CN=C1.CN1CCC[C@H]1C1=CC=CN=C1 IECQULMJVNSKDB-RCWTXCDDSA-N 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- 206010013911 Dysgeusia Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 238000012404 In vitro experiment Methods 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- JUGOREOARAHOCO-UHFFFAOYSA-M acetylcholine chloride Chemical compound [Cl-].CC(=O)OCC[N+](C)(C)C JUGOREOARAHOCO-UHFFFAOYSA-M 0.000 description 2
- 229960004266 acetylcholine chloride Drugs 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- WDIHJSXYQDMJHN-UHFFFAOYSA-L barium chloride Chemical compound [Cl-].[Cl-].[Ba+2] WDIHJSXYQDMJHN-UHFFFAOYSA-L 0.000 description 2
- 229910001626 barium chloride Inorganic materials 0.000 description 2
- 238000010009 beating Methods 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- ZHIBQGJKHVBLJJ-UHFFFAOYSA-N histamine phosphate Chemical compound OP(O)(O)=O.OP(O)(O)=O.NCCC1=CNC=N1 ZHIBQGJKHVBLJJ-UHFFFAOYSA-N 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 229940124606 potential therapeutic agent Drugs 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 210000005245 right atrium Anatomy 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 239000003506 spasmogen Substances 0.000 description 2
- 239000008399 tap water Substances 0.000 description 2
- 235000020679 tap water Nutrition 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- XBZYWSMVVKYHQN-MYPRUECHSA-N (4as,6as,6br,8ar,9r,10s,12ar,12br,14bs)-10-hydroxy-2,2,6a,6b,9,12a-hexamethyl-9-[(sulfooxy)methyl]-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-4a-carboxylic acid Chemical compound C1C[C@H](O)[C@@](C)(COS(O)(=O)=O)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C XBZYWSMVVKYHQN-MYPRUECHSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 241000252983 Caecum Species 0.000 description 1
- 241001633683 Centipeda <firmicute> Species 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 208000002881 Colic Diseases 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 101100129915 Escherichia coli (strain K12) melB gene Proteins 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 241001673526 Lydia Species 0.000 description 1
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 1
- 101800000989 Oxytocin Proteins 0.000 description 1
- 102100031951 Oxytocin-neurophysin 1 Human genes 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- 206010036595 Premature delivery Diseases 0.000 description 1
- 206010038419 Renal colic Diseases 0.000 description 1
- 241000120622 Rhizophoraceae Species 0.000 description 1
- 241000208460 Salvadoraceae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 102000003425 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- 241001123263 Zostera Species 0.000 description 1
- JILKNWYEDGFQNQ-UHFFFAOYSA-L [Cl-].[Ba+2].OS([O-])(=O)=O Chemical compound [Cl-].[Ba+2].OS([O-])(=O)=O JILKNWYEDGFQNQ-UHFFFAOYSA-L 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000003373 anti-fouling effect Effects 0.000 description 1
- 230000036436 anti-hiv Effects 0.000 description 1
- 229940124575 antispasmodic agent Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000002763 arrhythmic effect Effects 0.000 description 1
- 230000001746 atrial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 238000000262 chemical ionisation mass spectrometry Methods 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 239000002026 chloroform extract Substances 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000012847 fine chemical Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 239000003455 ganglion stimulating agent Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000000077 insect repellent Substances 0.000 description 1
- 210000005246 left atrium Anatomy 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 210000000713 mesentery Anatomy 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 201000003152 motion sickness Diseases 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 1
- 229960001723 oxytocin Drugs 0.000 description 1
- 238000005325 percolation Methods 0.000 description 1
- 210000001986 peyer's patch Anatomy 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000246 remedial effect Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 239000013535 sea water Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 230000016160 smooth muscle contraction Effects 0.000 description 1
- 239000000050 smooth muscle relaxant Substances 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 238000000935 solvent evaporation Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000001562 sternum Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
Definitions
- the invention relates to biologically active chloroform fraction of extracts obtained from the plant Salvadora persica Linneaus 1753.
- the invention also provides a process for obtaining the crude extract and obtaining the chloroform fraction.
- the invention provides pharmaceutical compositions, exhibiting biological activity.
- the associated mangrove plant, Salvadora persica Linneaus, 1753 belongs to the order Salvadoracea and are shrubs or small trees with white flowers frequent in degraded mangrove swamps and saline banks all over the west coast of India. Large numbers of marine plants have been examined for bioactive substances. Nazarine, F; Anita F; Rataboli, P. V.; Diniz D'Souza, R. S and Dhume; V. G., 1998 in Indian Journal of marine Sciences, 27: 499-501 have reported promising pharmacological activities in marine organisms from Indian waters.
- Betulinic acid which is prepared from the compound Betulin has many pharmaceutical potentials.
- Pezzuto John M; Kim; Darrick S. H. L. disclosed methods of manufacturing betulinic acid from betulin (U.S. Pat. No. 5,804,575 published on Sep. 8, 1998).
- the betulinic acid is intensively investigated as a potential therapeutic agent for a variety of diseases. Pezzuto; John, M; Das Gupta, Tapas K; Schmidt; Mary Lou; Kuzinanoff; Konrad Marc; Ling Indeck; Lydia and Kim; Darrick, S. H. L. (U.S. Pat. No. 5,962,527 dated Oct. 5, 1999).
- betulinic acid has an unexpected selective antitumour activity against human melanoma e.g. MEL-1, MEL-2 and MEL-4.
- Ursolic acid was one of the compound amongst a group of three compounds which was added to a flavored product to reduce aftertaste in the product and enhance its sweetness like in a diet drink. It was also used as a constituent in a preparation for inhibition of skin Tumorigenesis.
- Herman, S (U.S. Pat. No. 5,190,979 published on Mar. 2, 1993) disclosed lupeol also as a compound which can make pharmacologically active terpene ozonides which have medicinal value.
- the main object of the present invention is to provide a process for obtaining the chloroform fraction from the crude extract from stem, leaves, and flowers of Salvadora persica , a commonly available shrub in mangrove swamps and screening to study its bioactivity.
- Another object of the invention is to isolate naturally occurring compounds from the plant Salvadora persica and identify their molecular weights, molecular formulae, melting points and their structural formulae, which will be helpful in chemical synthesis of these compounds.
- Yet another object of the invention relates to the pharmacological screening of the chloroform fraction of the crude extract, its fractions and purified compounds to check that the activities shown by the crude extract and chloroform fraction are maintained throughout.
- Another object of the invention is to provide pharmaceutical compositions containing chloroform fraction of the extract from the plant Salvadora persica and exhibiting biological activity.
- the present invention seeks to overcome the drawbacks inherent in the prior art by providing the highly efficient and selective means for processing of active crude extract its fractionation, isolation and purification of the active compounds. Further, the invention provides pharmaceutical compositions containing the extract obtained from the plant Salvadora persica.
- the present invention discloses for the first time the methods of isolation, purification and pharmacological screening of all these above said commercially important compounds from a commonly available plant from mangrove swamps of the west coast of India.
- the said plant identified as Salvadora persica is an associated mangrove plant. It is a shrub and the twigs with leaves of flowers can be hand picked. Even the crude extract and fractions exhibit therapeutic value.
- the important point is that the biological activity shown by the extract is maintained in the purified compounds such as Methyl palmitate and Betulin.
- This disclosure points towards future potential clinical uses of the extract and fractions for treatment of diseases such as smooth muscle relaxant, bronchial asthma, renal colics and prevention of premature delivery. It further relates to the use of Methyl palmitate and Betulin in motion sickness, abdominal cramps.
- the invention provides methods whereby biologically active crude extract of an associated mangrove plant identified as Salvadora persica Linneaus 1753 is prepared.
- Salvadora persica Linneaus (Salvadoraceae) are shrubs or small trees with white flowers frequent in degraded mangrove swamps and saline banks all over the west coast of India; west Asia.
- the process disclosed in the invention further relates to the extraction, fractionation and purification of active constituent metabolites of the said plant.
- the invention is also concerned with the spectral identification of the compounds such as ⁇ -amyrin (non-steroidalpolycyclic triterpene), Betulin, Ursolic acid (triterpenic acid), Methyl palmitate (Aliphatic Ester) and Lupeol (non-steroidalpolycylic triterpene).
- the invention also deals with molecular formulae, molecular weights, melting points and structural formulae of the said compounds.
- the invention provides a highly efficient and selective means for processing of active crude extract obtained from Salvadora persica , its fractionation, isolation and purification.
- fractionation means separating the crude extract.
- isolation and fractionation means separating the fraction into pure compounds.
- the invention further relates to methods of screening pharmacological activities of the said compounds in mammalian tissues.
- the applicant has found that the crude extract obtained from the plant Salvadora persica can be separated into two fractions, i.e., chloroform and aqueous fractions.
- the chloroform fraction exhibits antispasmodic, anti-cholinergic and anti-arrhythmic activities which is described in detail in the present invention.
- the invention has a different approach for pharmacological screening of anti-arrhythmic activity on atrial tissues.
- the left atrium was used for electric stimulations rather than the right atrium which has the pacemaker. This method was found advantageous for longer survival of the atrium during experiments.
- the invention provides a process of extracting and purifying biologically useful molecules from an associated mangrove plant which comprises the steps of:
- the chloroform fraction of the mangrove plant Salvadora persica showed arrhythmic, anti-spasmodic, anti-cholinergic activity, as the parent crude extract.
- the invention also provides the identification of the molecules from the spectral data.
- the molecular formulae of the five compounds is provided from the spectral data.
- the invention provides molecular weights of the molecules from EIMS.
- the structural formulae of the compounds is also provided from the spectral data.
- a crude extract was obtained from the plant Salvadora persica .
- the crude extract was tested for its bioactivity and if found promising in terms of its pharmacological activity, it was fractionated using solvents with increasing polarity to obtain fractions such as petroleum ether, chloroform, butanol and aqueous. Each of these were also tested for their pharmacological activity.
- the five compounds purified from the extract of the plant were ⁇ -amyrin (non-steroidalpolycyclic triterpene), Betulin, Ursolic acid (triterpenic acid), Methyl palmitate (Aliphatic Ester) and Lupeol (non-steroidalpolycyclic triterpene).
- ⁇ -amyrin was found to be a non-steroidalpolycyclic triterpene with the following details:
- Ursolic acid triterpenic acid
- Methyl palmitate (Aliphatic Ester) found in the extract had:
- Betulinic acid is intensively investigated as a potential therapeutic agent for a variety of diseases.
- Ursolic acid is added to a flavored product to reduce after taste in the product and enhance its sweetness for example in a diet drink. It was also used as a constituent in a preparation for inhibition of skin Tumorigenesis.
- Extracts of some plants show vasoconstrictor and analgesic properties and also contain triterpenoid beta.-amyrin.
- These compositions for inhibiting the formation of unwanted skin pigmentation combine high tyrosinase blocking capabilities with stability in cosmetic preparations, absence of significant cytotoxic effects and synergy of action (U.S. Pat. No. 5,773,014, 5,679,393).
- Beta.-amyrin and lupeol are used as components for dimethylsterols in medical formulations (U.S. Pat. No. 4,808,574).
- Methyl palmitate is compound used in making alcohols as mentioned in U.S. Pat. No. 6,049,013 published on April, 2000.
- Lupeol can be used as a component for several remedial medicines, insect repellants, distilleries anti tumor and chemical industries (U.S. Pat. Nos. 4,808,574; 5,962,527; 5,908,628).
- the extract of Salvadora persica contained several compounds as listed above.
- the chloroform fraction of the extract of the said plant Salvadora persica was then tested for its biological activity on guinea pigs.
- the invention provides compositions containing the chloroform fraction of the extract obtained from Salvadora persica , optionally with conventional additives for inhibition of treatment of anti-cholinergic conditions such as asthma.
- the composition may contain about 10 ⁇ m of the extract.
- the chloroform fraction of the extract obtained from the plant Salvadora persica is a potential anti-cholinergic agent.
- the compositions may be formulated in different physical forms, as may be required.
- the extract may be used as such or with conventional additives, physiologically acceptable carriers, preservatives, buffers, etc. as required.
- the invention provides a method of treating anti-cholinergic conditions such as bronchial asthma, which comprises administration of therapeutically effective amount of extract obtained from Salvadora persica to the subject in need thereof.
- the extract may be administered at a dosage level in the range of 50 ⁇ g/ml to 250 ⁇ g/ml, in case of normal adults.
- the exact dosage will vary depending on the patient to be treated and will depend on factors such as requirements of the patient, severity of the condition being treated and the activity of the extract. The determination of optimum dosages for a particular patient is well-known to those skilled in the art.
- the invention provides compositions containing the chloroform fraction of the extract obtained from Salvadora persica , optionally with conventional additives for inhibition of treatment of spasmodic condition such as muscular spasms.
- the composition may contain about 10 ⁇ m of the extract.
- the chloroform fraction of the extract obtained from the plant Salvadora persica is a potential anti-spasmodic agent.
- the compositions may be formulated in different physical forms, as may be required.
- the extract may be used as such or with conventional additives, physiologically acceptable carriers, preservatives, buffers, etc. as required.
- the invention provides a method of treating spasmodic conditions such as bronchial asthma, which comprises administration of therapeutically effective amount of extract obtained from Salvadora persica to the subject in need thereof.
- the extract may be administered at a dosage level in the range of 50 ⁇ g/ml to 250 ⁇ g/ml, in case of normal adults.
- the exact dosage will vary depending on the patient to be treated and will depend on factors such as requirements of the patient, severity of the condition being treated and the activity of the extract. The determination of optimum dosages for a particular patient is well-known to those skilled in the art.
- the invention provides compositions containing the chloroform fraction of the extract obtained from Salvadora persica , optionally with conventional additives for inhibition of treatment of arrhythmias of the heart.
- the composition may contain about 10 ⁇ m of the extract.
- the chloroform fraction of the extract obtained from the plant Salvadora persica is a potential anti-arrhythmic agent.
- the compositions may be formulated in different physical forms, as may be required.
- the extract may be used as such or with conventional additives, physiologically acceptable carriers, preservatives, buffers, etc. as required.
- the invention provides a method of treating arrhythmias of the heart, which comprises administration of therapeutically effective amount of extract obtained from Salvadora persica to the subject in need thereof.
- the extract may be administered at a dosage level in the range of 3 ⁇ g/ml to 10 ⁇ g/ml, in case of normal adults.
- the extract is administered to the subject for a period of 10 minutes.
- the exact dosage will vary depending on the patient to be treated and will depend on factors such as requirements of the patient, severity of the condition being treated and the activity of the extract. The determination of optimum dosages for a particular patient is well-known to those skilled in the art.
- FIG. 1( a ) shows the mangrove plant
- FIG. 1( b ) shows the twig of the associated mangrove plant used.
- FIG. 2 shows the different fractions obtained from the extract of the plant Salvadora persica.
- FIG. 3 shows the structural formula of ⁇ -amyrin (non-steroidalpolycyclic triterpene)
- FIG. 4 shows the structural formula of Betulin
- FIG. 5 shows the structural formula of Ursolic acid (triterpenic acid),
- FIG. 6 shows the structural formula of Methyl palmitate (Aliphatic Ester)
- FIG. 7 shows the structural formula of Lupeol (non-steroidalpolycyclic triterpene).
- FIG. 8 shows the fractionation chart of extract of Salvadora persica
- This Example Provide Information About the Chemicals, Reagents, Apparatus Used and Their Sources.
- the crude extract was partitioned into petroleum ether, chloroform, n-butanol and aqueous fractions using a separating funnel. Petroleum ether was added to the extract in the separating funnel and separated out. Next, chloroform was added to the residue, mixed well and the lower layer separated. To the residue butanol was added and the top layer represented the butanol fraction and the lower layer was the aqueous fraction. Extraction of each fraction was done thrice and whenever there was emulsion, sodium chloride was added for breaking the emulsion. Sodium sulphate was added to chloroform and butanol fractions to remove traces of water before concentration. All the fractions were concentrated in the same manner as the crude extract.
- the active chloroform fraction of the mangrove plant S. persica was column chromatographed over silica gel for the isolation of the active constituent. Elutes from the column with the same TLC profile were mixed and subjected to pharmacological testing. The active sub-fractions were further chromatographed till active pure compounds were obtained (Flow chart I). Spots on thin layer chromatography (TLC) were visualised by using iodine vapours and spraying with methanolic sulphuric acid.
- TLC TLC grade silica gel
- Acetylcholine chloride (Hopkin & Williams Ltd) on ileum.
- Nicotine sulphate (BDH Chemicals) on intestine as ganglion stimulant.
- the isolated guinea pig ileum was used to study the anti-spasmodic, anti-cholinergic and anti-arrhythmic activity.
- the active fractions were isolated for anti-cholinergic activity, the five compounds isolated were tested only on isolated guinea-pig ileum.
- the longitudinal ileal muscle from a freshly killed guinea-pig was suspended in an organ bath of 10 ml capacity, filled with Tyrode solution and aerated with air.
- Tyrode solution comprised of:
- the active fractions were isolated for anti-spasmodic activity, the five compounds isolated were tested only on isolated guinea-pig ileum.
- the longitudinal ileal muscle from a freshly killed guinea-pig was suspended in an organ bath of 10 ml capacity, filled with Tyrode solution and aerated with air.
- guinea pig ileum For pharmacological testing on guinea pig ileum, the guinea-pig was sacrificed by stunning with a sharp blow on its head. The abdomen was quickly cut open. Towards the lower end of the abdomen was the greenish sac-like caecum. The small intestine was marked by a localized thickening in the wall—a Peyer's patch of lymphoid tissue. The lowermost 10 cm of ileum nearest to the ileocaecal junction was discarded. From there, about 10 cm of ileal tissue was cut off and freed of mesentery and placed in a petridish containing warm Tyrode solution.
- the lumen of the ileum was gently rinsed out using a hypodermic syringe filled with Tyrode solution to prevent accumulation of mucus in the lumen.
- the ileum was cut into small segments of about 3-4 cms in length in the fully relaxed state.
- the lower end was sutured to a tissue holder, by making a loop first to avoid direct contact with the tube.
- the tissue was positioned in an organ bath of capacity 10 ml containing Tyrode solution aerated with air at 37° C.
- the thread of the upper end of the ileum was fixed to the lever of a force transducer (FT 03) which measures muscle contractions isometrically and connected to a Grass Polygraph (Model 7).
- the ileal tissue was kept to stabilize in Tyrode solution for 30 minutes and the fluid in the organ bath was renewed every 10 mins (as pH changes).
- the thorax of the stunned guinae pig was quickly opened by cutting the sternocostal junctions.
- the heart was seen behind the sternum, beating in its pericardial covering. It was nicked off and placed in a petridish containing Ringer-Locke solution aerated with pure oxygen. It was gently squeezed to remove blood from the cavities of the atria and the ventricles and to prevent clotting of blood inside the coronary arteries. All other tissues were cut away until nothing was left except the auricles which appeared as a pair of rapidly beating pale pink leafy structures. Threads were tied one to the tip of each auricle.
- the right atrium having the pacemaker was tied to the glass oxygen tube and mounted in an organ bath of capacity 40 ml containing Ringer-Locke solution at 34° C. and oxygenated.
- the thread at the other end of the left auricle was fixed to the transducer (Force transducer T-305) which was connected to a Biodevices Physiograph.
- the composition of Ringer-Locke solution was:
- the sensitivity on the Physiograph was adjusted according to the heart beat.
- the auricles were fixed in a pair of stimulating electrodes, kept vertically immersed inside the bath. The auricles were allowed to equilibrate for a period of 30 minutes.
- the electrode was connected to a stimulator (Medicare Research Stimulator SS44) at a duration of 5 ⁇ 1 misec and 5 ⁇ 0.1 misec delay kept constant. Initially the voltage and frequency were minimum. Then the voltage was gradually increased till there was a change in amplitude. Then the frequency was increased/adjusted to get arrhythmias. Doses of extract/fraction were given as concentrations of the salt per ml of bath solution and allowed to remain in contact with the auricles for 10 minutes.
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a process of extracting, fractionating and purifying bioactive molecules from an associated mangrove plant, methods of screening for pharmacological activities of crude extract, its fractions and purified compounds and use of the chloroform fraction of the crude extract as anti-spasmodic, anti-arrhythmic and anti-cholinergic agent.
Description
- The invention relates to biologically active chloroform fraction of extracts obtained from the plantSalvadora persica Linneaus 1753. The invention also provides a process for obtaining the crude extract and obtaining the chloroform fraction. Further, the invention provides pharmaceutical compositions, exhibiting biological activity. Related Art The associated mangrove plant, Salvadora persica Linneaus, 1753, belongs to the order Salvadoracea and are shrubs or small trees with white flowers frequent in degraded mangrove swamps and saline banks all over the west coast of India. Large numbers of marine plants have been examined for bioactive substances. Nazarine, F; Anita F; Rataboli, P. V.; Diniz D'Souza, R. S and Dhume; V. G., 1998 in Indian Journal of marine Sciences, 27: 499-501 have reported promising pharmacological activities in marine organisms from Indian waters.
- There are several patents available from all over the world related to processes and compounds from nature for various purposes. Kwak; Wie-jong; Han; Chang-kyun; kum; Hwan-su; An; Jae-suk; Kum; Taek-soo, patented process of extracting and purifying biologically effective ingredients from combined medicinal plant and their extract composition (U.S. Pat. No. 5,910,307 published on Jun. 8, 1999). D'Amelio; Frank S; Mirhom; Youssef W. disclosed therapeutic composition and method for treating skin using extract fromCentipeda cunninghami plant in U.S. Pat. No. 5,804,206 published on Sep. 8, 1998. Zimmerman; Richard C.; Alber; Randall S.; Todd; James S.; Crews; philip, isolated compound from the methanolic extract of the eelgrass Zostrea marina having significant antifouling aquatic properties (U.S. Pat. No. 5,607,741 published on Mar. 4, 1997).
- Betulinic acid which is prepared from the compound Betulin has many pharmaceutical potentials. Pezzuto John M; Kim; Darrick S. H. L. disclosed methods of manufacturing betulinic acid from betulin (U.S. Pat. No. 5,804,575 published on Sep. 8, 1998). The betulinic acid is intensively investigated as a potential therapeutic agent for a variety of diseases. Pezzuto; John, M; Das Gupta, Tapas K; Schmidt; Mary Lou; Kuzinanoff; Konrad Marc; Ling Indeck; Lydia and Kim; Darrick, S. H. L. (U.S. Pat. No. 5,962,527 dated Oct. 5, 1999). Pisha E, Chai H, Lee I S, Chagwedera T E, Framsworth N R, Cordell G A, Beecher C W, Fong H H, Kinghorn A D, Brown D M, in Nature medicine, 1 pages 1046-1051 (1995) discloses that betulinic acid has an unexpected selective antitumour activity against human melanoma e.g. MEL-1, MEL-2 and MEL-4. In addition Fujioka T, Kashiwada Y, Kilkuskie R E, Cosentino L M, Ballas L M, Jiang J B, Janzen W P, Chen IS, Lee K H. J. Nat. Prod., 57 (2) pages 243-247 (1994) discloses that betulinic acid has anti-HIV activity in H9 lymphocytic cells. These inventors mentioned that the researches directed t betulinic acid as therapeutic agent are hindered because the betulinic acid is available in very limited quantities and at a very high cost. Ramadoss, Sunder, Jaggi, Manu; Siddiqui; Mohammad Jamshed Ahmed in U.S. Pat. No. 6,048,847 published on Apr. 11, 2000 describes uses of betulinic acid and its derivatives for inhibiting cancer growth and a method of monitoring this. Kang; Raphael K. L.; Zyzak; Li Li; Nakatsu; Tetsuo published flavored product additives in U.S. Pat. No. 5,948,460, dated Sep. 7, 1999 in which Ursolic acid was one of the compound amongst a group of three compounds which was added to a flavored product to reduce aftertaste in the product and enhance its sweetness like in a diet drink. It was also used as a constituent in a preparation for inhibition of skin Tumorigenesis.
- Herman, S (U.S. Pat. No. 5,190,979 published on Mar. 2, 1993) disclosed lupeol also as a compound which can make pharmacologically active terpene ozonides which have medicinal value.
- The main object of the present invention is to provide a process for obtaining the chloroform fraction from the crude extract from stem, leaves, and flowers ofSalvadora persica, a commonly available shrub in mangrove swamps and screening to study its bioactivity.
- Another object of the invention is to isolate naturally occurring compounds from the plantSalvadora persica and identify their molecular weights, molecular formulae, melting points and their structural formulae, which will be helpful in chemical synthesis of these compounds.
- Yet another object of the invention relates to the pharmacological screening of the chloroform fraction of the crude extract, its fractions and purified compounds to check that the activities shown by the crude extract and chloroform fraction are maintained throughout.
- Another object of the invention is to provide pharmaceutical compositions containing chloroform fraction of the extract from the plantSalvadora persica and exhibiting biological activity.
- The present invention seeks to overcome the drawbacks inherent in the prior art by providing the highly efficient and selective means for processing of active crude extract its fractionation, isolation and purification of the active compounds. Further, the invention provides pharmaceutical compositions containing the extract obtained from the plantSalvadora persica.
- The present invention discloses for the first time the methods of isolation, purification and pharmacological screening of all these above said commercially important compounds from a commonly available plant from mangrove swamps of the west coast of India. The said plant identified asSalvadora persica, is an associated mangrove plant. It is a shrub and the twigs with leaves of flowers can be hand picked. Even the crude extract and fractions exhibit therapeutic value. The important point is that the biological activity shown by the extract is maintained in the purified compounds such as Methyl palmitate and Betulin.
- This disclosure points towards future potential clinical uses of the extract and fractions for treatment of diseases such as smooth muscle relaxant, bronchial asthma, renal colics and prevention of premature delivery. It further relates to the use of Methyl palmitate and Betulin in motion sickness, abdominal cramps.
- The invention provides methods whereby biologically active crude extract of an associated mangrove plant identified asSalvadora persica Linneaus 1753 is prepared. Salvadora persica Linneaus (Salvadoraceae) are shrubs or small trees with white flowers frequent in degraded mangrove swamps and saline banks all over the west coast of India; west Asia. The process disclosed in the invention further relates to the extraction, fractionation and purification of active constituent metabolites of the said plant. The invention is also concerned with the spectral identification of the compounds such as β-amyrin (non-steroidalpolycyclic triterpene), Betulin, Ursolic acid (triterpenic acid), Methyl palmitate (Aliphatic Ester) and Lupeol (non-steroidalpolycylic triterpene). The invention also deals with molecular formulae, molecular weights, melting points and structural formulae of the said compounds. The invention provides a highly efficient and selective means for processing of active crude extract obtained from Salvadora persica, its fractionation, isolation and purification. As used herein, the terms fractionation means separating the crude extract. The term isolation and fractionation means separating the fraction into pure compounds.
- The invention further relates to methods of screening pharmacological activities of the said compounds in mammalian tissues. The applicant has found that the crude extract obtained from the plantSalvadora persica can be separated into two fractions, i.e., chloroform and aqueous fractions. The chloroform fraction exhibits antispasmodic, anti-cholinergic and anti-arrhythmic activities which is described in detail in the present invention.
- The invention has a different approach for pharmacological screening of anti-arrhythmic activity on atrial tissues. The left atrium was used for electric stimulations rather than the right atrium which has the pacemaker. This method was found advantageous for longer survival of the atrium during experiments.
- Accordingly, the invention provides a process of extracting and purifying biologically useful molecules from an associated mangrove plant which comprises the steps of:
- i) collecting and processing the plant plants ofSalvadora persica,
- ii) preparing a crude extract from the plant parts ofSalvadora persica,
- iii) testing the crude extract using methods of pharmacology,
- iv) fractionating the crude extract,
- v) testing the fractions using methods of pharmacology,
- vi) isolating the pure compounds by column chromatography,
- vii) testing the pure compounds by using methods of pharmacology, and
- viii) identifying the compounds by spectroscopy.
- According to another embodiment of the invention, the chloroform fraction of the mangrove plantSalvadora persica showed arrhythmic, anti-spasmodic, anti-cholinergic activity, as the parent crude extract.
- The invention also provides the identification of the molecules from the spectral data. The molecular formulae of the five compounds is provided from the spectral data. The invention provides molecular weights of the molecules from EIMS. The structural formulae of the compounds is also provided from the spectral data.
- Thus, a crude extract was obtained from the plantSalvadora persica. The crude extract was tested for its bioactivity and if found promising in terms of its pharmacological activity, it was fractionated using solvents with increasing polarity to obtain fractions such as petroleum ether, chloroform, butanol and aqueous. Each of these were also tested for their pharmacological activity.
- The five compounds purified from the extract of the plant were β-amyrin (non-steroidalpolycyclic triterpene), Betulin, Ursolic acid (triterpenic acid), Methyl palmitate (Aliphatic Ester) and Lupeol (non-steroidalpolycyclic triterpene).
- β-amyrin was found to be a non-steroidalpolycyclic triterpene with the following details:
- Molecular formula: C30H50O
- Molecular weight: 426
- Melting point: 160.degree C.
- Another molecule found was betulin having:
- Molecular formula: C30H50O
- Molecular weight: 442
- Melting point: 255 degree C.
- Ursolic acid (triterpenic acid) molecule was also found in the extract. It had:
- Molecular formula: C30H48O3
- Molecular weight: 456
- Melting point: 292 degree C.
- Methyl palmitate (Aliphatic Ester) found in the extract had:
- Molecular formula: C16H32O2
- Molecular weight: 256
- Melting point: 30 degree C.
- Lupeol (non-steroidalpolycyclic triterpene) found in the extract had:
- Molecular formula: C30H50O
- Molecular weight: 426
- Melting point: 215 degree. C.
- One of the compounds Betulin which can be used in manufacturing of betulinic acid (U.S. Pat. No. 5,804,575 published on Sep. 8, 1998. Betulinic acid is intensively investigated as a potential therapeutic agent for a variety of diseases.
- Ursolic acid is added to a flavored product to reduce after taste in the product and enhance its sweetness for example in a diet drink. It was also used as a constituent in a preparation for inhibition of skin Tumorigenesis.
- Extracts of some plants show vasoconstrictor and analgesic properties and also contain triterpenoid beta.-amyrin. These compositions for inhibiting the formation of unwanted skin pigmentation combine high tyrosinase blocking capabilities with stability in cosmetic preparations, absence of significant cytotoxic effects and synergy of action (U.S. Pat. No. 5,773,014, 5,679,393). Beta.-amyrin and lupeol are used as components for dimethylsterols in medical formulations (U.S. Pat. No. 4,808,574).
- Methyl palmitate is compound used in making alcohols as mentioned in U.S. Pat. No. 6,049,013 published on April, 2000. Lupeol can be used as a component for several remedial medicines, insect repellants, distilleries anti tumor and chemical industries (U.S. Pat. Nos. 4,808,574; 5,962,527; 5,908,628).
- Thus, the extract ofSalvadora persica contained several compounds as listed above. The chloroform fraction of the extract of the said plant Salvadora persica, was then tested for its biological activity on guinea pigs. The Applicants, to their surprise found that the extract exhibited excellent anti-cholinergic, anti-arrhythmic and anti-spasmodic activity.
- Accordingly, the invention provides compositions containing the chloroform fraction of the extract obtained fromSalvadora persica, optionally with conventional additives for inhibition of treatment of anti-cholinergic conditions such as asthma. The composition may contain about 10 μm of the extract. Thus, the chloroform fraction of the extract obtained from the plant Salvadora persica is a potential anti-cholinergic agent. The compositions may be formulated in different physical forms, as may be required. The extract may be used as such or with conventional additives, physiologically acceptable carriers, preservatives, buffers, etc. as required.
- Additionally, the invention provides a method of treating anti-cholinergic conditions such as bronchial asthma, which comprises administration of therapeutically effective amount of extract obtained fromSalvadora persica to the subject in need thereof. The extract may be administered at a dosage level in the range of 50 μg/ml to 250 μg/ml, in case of normal adults. The exact dosage will vary depending on the patient to be treated and will depend on factors such as requirements of the patient, severity of the condition being treated and the activity of the extract. The determination of optimum dosages for a particular patient is well-known to those skilled in the art.
- Further, the applicant found that the chloroform fraction of the extract obtained from the plantSalvadora persica exhibits anti-spasmodic activity. Accordingly, the invention provides compositions containing the chloroform fraction of the extract obtained from Salvadora persica, optionally with conventional additives for inhibition of treatment of spasmodic condition such as muscular spasms. The composition may contain about 10 μm of the extract. Thus, the chloroform fraction of the extract obtained from the plant Salvadora persica is a potential anti-spasmodic agent. The compositions may be formulated in different physical forms, as may be required. The extract may be used as such or with conventional additives, physiologically acceptable carriers, preservatives, buffers, etc. as required.
- Additionally, the invention provides a method of treating spasmodic conditions such as bronchial asthma, which comprises administration of therapeutically effective amount of extract obtained fromSalvadora persica to the subject in need thereof. The extract may be administered at a dosage level in the range of 50 μg/ml to 250 μg/ml, in case of normal adults. The exact dosage will vary depending on the patient to be treated and will depend on factors such as requirements of the patient, severity of the condition being treated and the activity of the extract. The determination of optimum dosages for a particular patient is well-known to those skilled in the art.
- Furthermore, the applicant found that the chloroform fraction of the extract obtained from the plantSalvadora persica exhibits anti-arrhythmic activity. Accordingly, the invention provides compositions containing the chloroform fraction of the extract obtained from Salvadora persica, optionally with conventional additives for inhibition of treatment of arrhythmias of the heart. The composition may contain about 10 μm of the extract. Thus, the chloroform fraction of the extract obtained from the plant Salvadora persica is a potential anti-arrhythmic agent. The compositions may be formulated in different physical forms, as may be required. The extract may be used as such or with conventional additives, physiologically acceptable carriers, preservatives, buffers, etc. as required.
- Additionally, the invention provides a method of treating arrhythmias of the heart, which comprises administration of therapeutically effective amount of extract obtained fromSalvadora persica to the subject in need thereof. The extract may be administered at a dosage level in the range of 3 μg/ml to 10 μg/ml, in case of normal adults. The extract is administered to the subject for a period of 10 minutes. The exact dosage will vary depending on the patient to be treated and will depend on factors such as requirements of the patient, severity of the condition being treated and the activity of the extract. The determination of optimum dosages for a particular patient is well-known to those skilled in the art.
- FIG. 1(a) shows the mangrove plant and
- FIG. 1(b) shows the twig of the associated mangrove plant used.
- FIG. 2 shows the different fractions obtained from the extract of the plantSalvadora persica.
- FIG. 3 shows the structural formula of β-amyrin (non-steroidalpolycyclic triterpene)
- FIG. 4 shows the structural formula of Betulin,
- FIG. 5 shows the structural formula of Ursolic acid (triterpenic acid),
- FIG. 6 shows the structural formula of Methyl palmitate (Aliphatic Ester)
- FIG. 7 shows the structural formula of Lupeol (non-steroidalpolycyclic triterpene).
- FIG. 8 shows the fractionation chart of extract ofSalvadora persica
- The invention is described in detail and illustrated by the following examples which should not be construed as limitations on the inventive concept embodied herein.
-
Name of reagent/chemicals Company Aqueous methanol Sisco Research Laboratories Pvt Ltd. Petroleum ether Ranbaxy Fine Chemicals Ltd. Chloroform Sisco Research Laboratories Pvt Ltd. Butanol Sisco Research Laboratories Pvt Ltd. Ethyl acetate Sisco Research Laboratories Pvt Ltd. Histamine acid phosphate Blenkinsop & Co. Ltd Acetylcholine chloride Hopkin & Williams Ltd. 5-Hydroxytryptamine creatine Sigma Chemicals sulphate Barium chloride Apex Chemicals Nicotine sulphate BDH chemicals Oxytocin Parke Davis India Ltd. Prostodin- PGF 2 alphaAstra IDL Ltd. - Apparatus:
- 1. Physiograph.
- Company: Biodevices,
- Ambala, India.
- 2. Force Transducer
- Model No. T-305
- Co.: GRASS, USA
- 3. Stimulator
- Model SS44
- Co. Biodevices, Ambala
- 4. Polygraph
- Model 7
- Co. GRASS, USA.
- 5. Force Transducer
- Model No. FT-03
- Co.: GRASS, USA
- 6. Organ Bath
- Ambala,
- India
- Collection of the mangrove plantSalvadora persica L from the coast of Goa, a state in India was along Ribandar, near the mouth of the Mandovi estuary, upstream. This species is ubiquitous to the coastal areas of Goa and was collected manually from the intertidal banks.
- Processing of the collected mangroves were washed first with seawater followed by tap water. The undesired materials were sifted out while washing with tap water to get rid of the salts. The leaves, stems, and flowers of the associated mangrove plant were air dried. After drying, the plant material was cut into small pieces and immersed in the solvent 90% aqueous methanol for a week for extraction. Care was taken to ensure that these were properly soaked/dipped in the solvent and checked for putrefaction.
- Extraction and preparation of crude extract was carried out by cold percolation method at room temperature and by solvent evaporation at a water bath (temperature 50° C.) under reduced pressure. This helps in protection of any heat labile metabolite present in it. Re-extraction was done twice until the extract was concentrated under vacuum to obtain the crude extract.
- Fractionation of the Crude Extract
- The crude extract was partitioned into petroleum ether, chloroform, n-butanol and aqueous fractions using a separating funnel. Petroleum ether was added to the extract in the separating funnel and separated out. Next, chloroform was added to the residue, mixed well and the lower layer separated. To the residue butanol was added and the top layer represented the butanol fraction and the lower layer was the aqueous fraction. Extraction of each fraction was done thrice and whenever there was emulsion, sodium chloride was added for breaking the emulsion. Sodium sulphate was added to chloroform and butanol fractions to remove traces of water before concentration. All the fractions were concentrated in the same manner as the crude extract. These fractions were tested for the same pharmacological activity as the parent crude extract. Column chromatography for isolation of pure compound was done by repeated column chromatography and thin layer chromatography of the eluents. The TLC revealed compounds such as Beta-amyrin, betulin, ursolic acid and lupeol.
- To obtain the compounds Beta amyrin and betulin, separation by thin layer chromatography is carried out on 0.25 mm thick silica gel plates (Qualigen). The eluent is an 90:10 (v/v) Petroleum ether/ethyl acetate mixture and the spots are developed by spraying with 5% H2SO4 solution and fixation by heating at 110.degree. C.
- For compounds Ursolic acid and Methyl palmitate separation by thin layer chromatography was carried out on 0.25 mm thick silica gel plates (Qualigen). The eluent is an 85:15 (v/v) Petroleum ether/ethyl acetate mixture and the spots are developed by spraying with a 5% H2SO4 solution and fixation by heating at 110° C.
- For the compound lupeol the separations by thin layer chromatography are carried out on 0.25 mm thick silica gel plates (Qualigen). The eluent is an 75:25 (v/v) Petroleum ether/ethyl acetate mixture and the spots are developed by spraying with a 5% H2SO4 solution and fixation by heating at 110.degree. C.
- In the present invention, the active chloroform fraction of the mangrove plantS. persica, was column chromatographed over silica gel for the isolation of the active constituent. Elutes from the column with the same TLC profile were mixed and subjected to pharmacological testing. The active sub-fractions were further chromatographed till active pure compounds were obtained (Flow chart I). Spots on thin layer chromatography (TLC) were visualised by using iodine vapours and spraying with methanolic sulphuric acid.
- TLC was done on glass plates (20×20 cms) coated with a 0.25 mm layer of TLC grade silica gel (Qualigens) activated at 110° C. for 1 hour before use. The active aqueous fraction was passed through XAD-column and eluents were treated, as mentioned above, for the isolation and purification of active constituent metabolites.
- The five compounds were identified on the basis of spectral data obtained at the Regional Sophisticated Instrumentation Center (RSIC) India by the following spectra:
-
- Apparatus: Bruker Spectrometer
- Model: DPX
- Co. Bruker
-
- The compounds were identified from a comparison of their spectral data with those of similar compounds reported in literature .
- Mass spectra (EIMS) electron impact Mass spectrometry for determining the molecular weights along with its fragmentation pattern were carried out on Mass spectrometer (E1/CIMS) Model D.300 JEOL,
- Apparatus: Mass Spectrometer (EIMS)
- Model: D-300
- Co. JEOL, Japan
- Pharmacological testing of pure compounds
- Standard drugs used were the following:
- Histamine acid phosphate (Blenkinsop & Co. Ltd) on ileum.
- Acetylcholine chloride (Hopkin & Williams Ltd) on ileum.
- 5-Hydroxytryptamine creatinine sulphate (sigma Chemicals Co.) on gastrointestinal tract. Barium chloride (Apex Chemicals) on smooth muscle contraction.
- Nicotine sulphate (BDH Chemicals) on intestine as ganglion stimulant.
- All other reagents used were of analytical grade.
- Tyrode was used on guinea-pig ileum and Ringer-Locke physiological solution was used on guinea-pig atria.
- All other reagents used were of analytical grade.
- Physiological solutions used and various parameters:
- All physiological solutions were prepared fresh at the time of the experiment.
- pH:
- The pH of the various physiological salt solutions varied between 7.3 & 7.4. At lower pH the tonus of the preparation tends to decrease and is therefore liable to alter the effect of drugs.
- Temperature:
- In order to get consistent effects it was important to maintain the temperature of the bath solution at a specified level, because if the temperature is decreased below 37° C., the tonus of the intestine is increased, the contractions become smaller and the contraction and relaxation times increased.
- Air:
- Air or oxygen is needed for proper functioning of the tissues. Besides, providing oxygen to the tissues, the stream of gas bubbles also stirred the bath solution thereby facilitating diffusion of drugs added to the bath.
- The solution in the bath was changed frequently because prolonged aeration tends to alter the pH.
- In vitro Experiments
- Female, virgin, guinea pigs weighing around 300 to 350 g, housed under uniform husbandry conditions (temperature 25±1° C.) were used. The animals were starved 24 hours prior to the experiment, only water was provided ad libitum.
- The isolated guinea pig ileum was used to study the anti-spasmodic, anti-cholinergic and anti-arrhythmic activity.
- A. Anti-Cholinergic Activity,
- The active fractions were isolated for anti-cholinergic activity, the five compounds isolated were tested only on isolated guinea-pig ileum. The longitudinal ileal muscle from a freshly killed guinea-pig was suspended in an organ bath of 10 ml capacity, filled with Tyrode solution and aerated with air. Tyrode solution comprised of:
- Glucose 1.0 g
- Sodium chloride 8.0 g
- Sodium bicarbonate 1.0 g
- Potassium chloride 0.2 g
- Calcium chloride 0.2 g
- Magnesium chloride 0.1 g
- Sodium hydrogen phosphate 0.05 g
- All were dissolved in 1000 ml distilled water
- Two to four doses of the standard drug acetylcholine were added to the bath to obtained uniform amplitude with a contact period of 30 seconds, the contractions of which were recorded on a polygraph. The five compounds isolated were tested in doses of 196 and 392×10−6 moles per ml of bath concentration. The effect of the compounds against acetylcholine-induced contraction was seen and the percentage reduction of contraction measured.
- B. Anti-Spasmodic Activity
- The active fractions were isolated for anti-spasmodic activity, the five compounds isolated were tested only on isolated guinea-pig ileum. The longitudinal ileal muscle from a freshly killed guinea-pig was suspended in an organ bath of 10 ml capacity, filled with Tyrode solution and aerated with air.
- For pharmacological testing on guinea pig ileum, the guinea-pig was sacrificed by stunning with a sharp blow on its head. The abdomen was quickly cut open. Towards the lower end of the abdomen was the greenish sac-like caecum. The small intestine was marked by a localized thickening in the wall—a Peyer's patch of lymphoid tissue. The lowermost 10 cm of ileum nearest to the ileocaecal junction was discarded. From there, about 10 cm of ileal tissue was cut off and freed of mesentery and placed in a petridish containing warm Tyrode solution. The lumen of the ileum was gently rinsed out using a hypodermic syringe filled with Tyrode solution to prevent accumulation of mucus in the lumen. The ileum was cut into small segments of about 3-4 cms in length in the fully relaxed state. The lower end was sutured to a tissue holder, by making a loop first to avoid direct contact with the tube. The tissue was positioned in an organ bath of capacity 10 ml containing Tyrode solution aerated with air at 37° C. The thread of the upper end of the ileum was fixed to the lever of a force transducer (FT 03) which measures muscle contractions isometrically and connected to a Grass Polygraph (Model 7). The ileal tissue was kept to stabilize in Tyrode solution for 30 minutes and the fluid in the organ bath was renewed every 10 mins (as pH changes).
- Two to four doses of the standard drug spasmogens (acetylcholine, histamine, 5-hydroxytryptamine, barium chloride and nicotine) were added to the bath to obtain uniform amplitude with a contact period of 60 seconds, the contractions of which were recorded on a polygraph. The chloroform extract was added one minute before addition of the spasmogens. The effect of the compounds against acetylcholine-induced contraction was seen and the percentage reduction of contraction measured.
- C. Anti-Arrhythmic Activity
- In Vitro experiments were performed on isolated guinea pig atria.
- The thorax of the stunned guinae pig was quickly opened by cutting the sternocostal junctions. The heart was seen behind the sternum, beating in its pericardial covering. It was nicked off and placed in a petridish containing Ringer-Locke solution aerated with pure oxygen. It was gently squeezed to remove blood from the cavities of the atria and the ventricles and to prevent clotting of blood inside the coronary arteries. All other tissues were cut away until nothing was left except the auricles which appeared as a pair of rapidly beating pale pink leafy structures. Threads were tied one to the tip of each auricle. The right atrium having the pacemaker was tied to the glass oxygen tube and mounted in an organ bath of capacity 40 ml containing Ringer-Locke solution at 34° C. and oxygenated. The thread at the other end of the left auricle was fixed to the transducer (Force transducer T-305) which was connected to a Biodevices Physiograph. The composition of Ringer-Locke solution was:
- Glucose 0.5 g
- Sodium chloride 9.0 g
- Sodium bicarbonate 0.5 g
- Potassium chloride 0.42 g
- Calcium chloride 0.24 g
- The sensitivity on the Physiograph was adjusted according to the heart beat. The auricles were fixed in a pair of stimulating electrodes, kept vertically immersed inside the bath. The auricles were allowed to equilibrate for a period of 30 minutes. The electrode was connected to a stimulator (Medicare Research Stimulator SS44) at a duration of 5×1 misec and 5×0.1 misec delay kept constant. Initially the voltage and frequency were minimum. Then the voltage was gradually increased till there was a change in amplitude. Then the frequency was increased/adjusted to get arrhythmias. Doses of extract/fraction were given as concentrations of the salt per ml of bath solution and allowed to remain in contact with the auricles for 10 minutes. After every alternate minute, the physiograph was run to see if there was any change in heart rate. After 10 minutes the auricles were stimulated twice for arrhythmias. The anti-arrhythmic effect of each dose i.e. 3 and 10 μg/ml was calculated. The formula used for evaluating the arrythmic effect of crude extract ofSalvadora persica on guinea pig atrium is:
- wherein
- X=Maximum frequency before the extract
- Y=Maximum frequency after the extract
- The relative in vitro effect ofSalvadora persica on guinea pig atrium is shown in the Table hereinbelow:
FREQUEN- CY PERCENT- FREQUENCY AFTER AGE EXTRACT TISSUE BEFORE DRUG DRUG CHANGE Crude Extract Atrium 96 beats/sec. 96 beats/sec. 0 - EXTRACT TISSUE FREQUENCY FREQUENCY PERCENTAGE BEFORE DRUG AFTER DRUG CHANGE Crude Extract Atrium 96 beats/sec. 96 beats/sec. 0
- Table showing the effect of extract on guinea pig atrium.
Claims (32)
1. A process for the extraction and purification of a biologically active extract from the plant Salvadora persica, comprising a steps of
i) collecting and processing the plant parts of Salvadora persica,
ii) preparing a crude extract from the plant parts of Salvadora persica,
iii) testing the crude extract using methods of pharmacology,
iv) fractionating the crude extract,
v) testing the fractions using methods of pharmacology,
vi) isolating the pure compounds by column chromatography,
vii) testing the pure compounds by using methods of pharmacology, and
viii) identifying the compounds by spectroscopy.
2. A process as claimed in claim 1 wherein the plant parts of Salvadora persica are selected from leaves, stems and flowers.
3. A process as claimed in claim 1 wherein the steps for preparation of a crude extract are:
(i) air-drying the plant parts,
(ii) immersing the plant parts in 90% aqueous methanol for one week, at room temperature (28±2° C.),
(iii) filtering the methanolic extract by conventional methods, and
(iv) evaporating the methanolic extract under reduced pressure at room temperature (28±2° C.) to a minimum quantity to obtain a crude extract.
4. A process as claimed in claim 1 wherein the crude extract is partitioned into four fractions using solvents selected from petroleum ether, chloroform, butanol and aqueous fraction.
5. A process as claimed in claim 1 wherein the chloroform fraction exhibits anti-cholinergic activity, anti-spasmodic and anti-arrhythmic activity.
6. A process as claimed in claim 1 wherein the chloroform fraction is passed through a silica gel column and then eluted using petroleum ether ethyl acetate-chloroform-methanol gradient system.
7. A process as claimed in claim 1 wherein the thin layer chromatography (TLC) was carried out on silica gel.
8. A process as claimed in claim 1 wherein the TLC was visualized either by exposing plates to iodine vapours or by spraying with methanolic sulphuric acid.
9. A process as claimed in claim 1 wherein the fractions which showed anti-cholinergic activity were pooled and passed through the silica gel column and eluted with same set of solvents.
10. A process as claimed in claim 1 wherein Methyl palmitate in the extract showed higher anti-cholinergic activity and Betulin showed mild anticholinergic activity.
11. A process as claimed in claim 1 wherein β-amyrin (non-steroidalpolycyclic triterpene) molecule is characterised by:
Molecular formula: C30H50O
Molecular weight: 426
Melting point: 160° C.
12. A process as claimed in claim 1 wherein Betulin molecule is characterised by:
Molecular formula: C30H50O2
Molecular weight: 442
Melting point: 255° C.
13. A process as claimed in claim 1 wherein Ursolic acid (triterpenic acid) molecule is characterised by:
Molecular formula: C30H50O3
Molecular weight: 456
Melting point: 292° C.
14. A process as claimed in claim 1 wherein Methyl palmitate (Aliphatic Ester) molecule is characterised by:
Molecular formula: C30H50O2
Molecular weight: 256
Melting point: 30° C.
15. A process as claimed in claim 1 wherein Lupeol (non-steroidalpolycyclic triterpene) molecule is characterised by:
Molecular formula: C30H50O
Molecular weight: 426
Melting point: 215° C.
16. A Pharmaceutical composition exhibiting anti-cholinergic, anti-spasmodic, and anti-arrhythmic activity, said composition comprising the chloroform fraction of the extract obtained from the plant Salvadora persica optionally, with conventional additives.
17. A composition as claimed in claim 16 wherein the additives are selected from therapeutically acceptable additives.
18. A composition as claimed in claim 16 wherein the extract contains compounds selected from β-amyrin, betulin, ursolic acid, methyl palmitate and lupeol.
19. A composition as claimed in claim 16 wherein the amount of extract in the composition is 10 μgms.
20. A composition as claimed in claim 16 wherein the dosage of the extract is 3 μg/ml to 10 μg/ml.
21. A method for the treatment of arrhythmias, said method comprising the step of administering a therapeutically effective amount of extract obtained from the plant Salvadora persica, optionally with conventional additives to a subject afflicted with arrhythmias.
22. A method as claimed in claim 21 wherein the extract obtained from the plant Salvadora persica, is a chloroform fraction.
23. A method as claimed in claim 21 wherein 3 to 10 μg/ml. amount of the extract is administered to the subject for a period of 10 minutes.
24. A method as claimed in claim 21 wherein the subject is a human or animal.
25. A method for the treatment of spasmodic conditions such as muscular spasms, said method comprising the step of administering a therapeutically effective amount of extract obtained from the plant Salvadora persica, optionally with conventional additives to a subject in need thereof.
26. A method as claimed in claim 25 wherein the extract obtained from the plant Salvadora persica, is a chloroform fraction of the crude extract of the plant Salvadora persica.
27. A method as claimed in claim 25 wherein 3 to 10 μg/ml. amount of the extract is administered to the subject for a period of 10 minutes.
28. A method as claimed in claim 25 wherein the subject is a human or animal.
29. A method for the treatment of cholinergic conditions such as bronchial asthma, said method comprising the step of administering a therapeutically effective amount of extract obtained from the plant Salvadora persica, optionally with conventional additives to a subject in need thereof.
30. A method as claimed in claim 29 wherein the extract obtained from the plant Salvadora persica, is a chloroform fraction of the crude extract.
31. A method as claimed in claim 29 wherein 3 to 10 μg/ml. amount of the extract is administered to the subject for a period of 10 minutes.
32. A method as claimed in claim 29 wherein the subject is a human or animal.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/818,691 US20030003171A1 (en) | 2001-03-28 | 2001-03-28 | Biologically active chloroform fraction of an extract obtained from a mangroone plant Salvadora persica L |
US10/180,062 US6753021B2 (en) | 2001-03-28 | 2002-06-27 | Biologically active chloroform fraction of an extract obtained from a mangrove plant Salvadora persica L |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/818,691 US20030003171A1 (en) | 2001-03-28 | 2001-03-28 | Biologically active chloroform fraction of an extract obtained from a mangroone plant Salvadora persica L |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/180,062 Continuation US6753021B2 (en) | 2001-03-28 | 2002-06-27 | Biologically active chloroform fraction of an extract obtained from a mangrove plant Salvadora persica L |
Publications (1)
Publication Number | Publication Date |
---|---|
US20030003171A1 true US20030003171A1 (en) | 2003-01-02 |
Family
ID=25226171
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/818,691 Abandoned US20030003171A1 (en) | 2001-03-28 | 2001-03-28 | Biologically active chloroform fraction of an extract obtained from a mangroone plant Salvadora persica L |
US10/180,062 Expired - Fee Related US6753021B2 (en) | 2001-03-28 | 2002-06-27 | Biologically active chloroform fraction of an extract obtained from a mangrove plant Salvadora persica L |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/180,062 Expired - Fee Related US6753021B2 (en) | 2001-03-28 | 2002-06-27 | Biologically active chloroform fraction of an extract obtained from a mangrove plant Salvadora persica L |
Country Status (1)
Country | Link |
---|---|
US (2) | US20030003171A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102998410A (en) * | 2011-09-13 | 2013-03-27 | 天士力制药集团股份有限公司 | Blood nourishing and brain arousing particle quality detection method |
CN103439446A (en) * | 2013-08-13 | 2013-12-11 | 张家港威胜生物医药有限公司 | Method for measuring content of betulin in birch bark by using RP-HPL method |
US20140079329A1 (en) * | 2012-09-18 | 2014-03-20 | Panasonic Corporation | Image decoding method and image decoding apparatus |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6956122B2 (en) * | 2001-09-05 | 2005-10-18 | Council Of Scientific & Industrial Research | Multiple fluorescent natural dye compound from a marine organism |
DE102013114608A1 (en) * | 2013-12-20 | 2015-07-09 | Endress + Hauser Gmbh + Co. Kg | Relative pressure sensor |
CN104225200A (en) * | 2014-09-30 | 2014-12-24 | 王林 | Traditional Chinese medicine for treating fluid retention invading heart-lung type cardiac asthma and preparation method thereof |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5190979A (en) | 1988-06-24 | 1993-03-02 | Stephen Herman | Ozonides of terpenes and their medical uses |
US5009886A (en) | 1989-10-02 | 1991-04-23 | Floss Products Corporation | Dentifrice |
US5384176A (en) | 1992-12-11 | 1995-01-24 | Zimmerman; Richard C. | Phenolic acid sulfate esters for prevention of marine biofouling |
US5962527A (en) | 1995-03-21 | 1999-10-05 | The Board Of Trustees Of The University Of Illinois | Method and composition for treating cancers |
US5781654A (en) * | 1996-01-18 | 1998-07-14 | Merrill Lynch & Co., Inc. | Check authentication system utilizing payee information |
EP0832652B8 (en) | 1996-09-19 | 2006-05-03 | Sk Chemicals Co., Ltd. | Process of extracting and purifying biologically effective ingredients from combined medicinal plants and their extract composition |
US5804206A (en) | 1997-03-06 | 1998-09-08 | Bio-Botanica, Inc. | Therapeutic composition and method for treating skin using Centipeda cunninghami extract |
US5804575A (en) | 1997-03-27 | 1998-09-08 | The Board Of Trustees Of The University Of Illinois | Methods of manufacturing betulinic acid |
US6048847A (en) | 1997-09-30 | 2000-04-11 | Dabur Research Foundation | Use of betulinic acid and its derivatives for inhibiting cancer growth and a method of monitoring this |
US5948460A (en) | 1998-07-27 | 1999-09-07 | Takasago International Corporation | Flavored product additive and method for using same |
-
2001
- 2001-03-28 US US09/818,691 patent/US20030003171A1/en not_active Abandoned
-
2002
- 2002-06-27 US US10/180,062 patent/US6753021B2/en not_active Expired - Fee Related
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102998410A (en) * | 2011-09-13 | 2013-03-27 | 天士力制药集团股份有限公司 | Blood nourishing and brain arousing particle quality detection method |
US20140079329A1 (en) * | 2012-09-18 | 2014-03-20 | Panasonic Corporation | Image decoding method and image decoding apparatus |
US9245356B2 (en) * | 2012-09-18 | 2016-01-26 | Panasonic Intellectual Property Corporation Of America | Image decoding method and image decoding apparatus |
CN103439446A (en) * | 2013-08-13 | 2013-12-11 | 张家港威胜生物医药有限公司 | Method for measuring content of betulin in birch bark by using RP-HPL method |
Also Published As
Publication number | Publication date |
---|---|
US6753021B2 (en) | 2004-06-22 |
US20020172731A1 (en) | 2002-11-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI92146C (en) | New cosmetic compositions | |
DE69824318T2 (en) | METHOD FOR THE PREPARATION AND PHARMACEUTICAL PREPARATION OF A WATER SOLUBLE UNCARIA EXTRACT | |
DE3688001T2 (en) | EXTRACTS OF COIX LACRYMA JOBI OR FERULYLSTANOL DERIVATIVES AND / OR FATTY ACID PHYTOSTEROLESTERS CONTAINING FERTILIZERS. | |
DE60206531T2 (en) | A HERB MOLECULE AS A POTENTIAL ANTI-LEUKEMIC MEDICINAL PRODUCT | |
Seriki et al. | Analysis of phytoconstituents of Desmodium adscendens in relation to its therapeutic properties | |
US6428823B1 (en) | Biologically active aqueous fraction of an extract obtained from a mangrove plant Salvadora persica L | |
US20030003171A1 (en) | Biologically active chloroform fraction of an extract obtained from a mangroone plant Salvadora persica L | |
KR100295366B1 (en) | Pathogenic extract with anti-inflammatory activity | |
EP1372681B1 (en) | Biologically active chloroform fraction of an extract obtained from a mangrove plant salvadora persica l | |
DE60104802T2 (en) | FOOD FOR PREVENTING LIVING DYSFUNCTION CONTAINING AN ALKANOYL L-CARNITINE AND A SILYBUM MARIANUM EXTRACT AND USE THEREOF | |
Hussain et al. | Pharmacological effects of Gardenia erubescens in mice, rats and cats | |
AU2001256656A1 (en) | Biologically active chloroform fraction of an extract obtained from a mangrove plant salvadora persica l | |
AU2001256653B2 (en) | Biologically active aqueous fraction of an extract obtained from a mangrove plant Salvadora persica L. | |
Olagbende-Dada et al. | Oxytocic and anti-implantation activities of the leaf extracts of Graptophyllum pictum (Linn.) Griff.(Acanthaceae) | |
Dixit et al. | A phytopharmacological review on an important medicinal plant-Wrightia tinctoria | |
AU2005202105B2 (en) | Biologically active aqueous fraction of an extract obtained from a mangrove plant Salvadora Persica L. | |
AU2001256653A1 (en) | Biologically active aqueous fraction of an extract obtained from a mangrove plant Salvadora persica L. | |
US20020182277A1 (en) | Bioactivity of methyl palmitate obtained from a mangroove plant Salvadora persica L | |
AU2001256651B2 (en) | Bioactivity of methyl palmitate obtained from a mangrove plant salvadora persica L | |
DE2265235A1 (en) | REMEDIES | |
EA045875B1 (en) | METHOD FOR OBTAINING PLANT EXTRACT WITH CARDIOPROTECTIVE EFFECT | |
DE102005060880A9 (en) | Special extract for use as antiarrhythmic agent in cardiac arrhythmias and to improve coronary perfusion and its production | |
AU2001256651A1 (en) | Bioactivity of methyl palmitate obtained from a mangrove plant salvadora persica L | |
DE102020007979A1 (en) | Composition for treating coronavirus infections | |
DE2350359C3 (en) | Medicines containing trans-isoasarone |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH, INDIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GOSWAMI, USHA;FERNANDES, NAZARINE;REEL/FRAME:011948/0554;SIGNING DATES FROM 20010522 TO 20010601 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |